BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:ABBV-932 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of ABBV-932\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06846320-11137@assetmemo.bio
DTSTAMP:20261121T004543Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:ABBV-932: Phase 2 readout est. (NCT06846320)
DESCRIPTION:ABBV-932\, phase 2.\nStudy: Study to Assess Adverse Events and 
 Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant T
 herapies in Adult Participants With Generalized Anxiety Disorder\nEstimate
 d primary completion: November 2026. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/abbv-932#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT06846320
URL:https://assetmemo.bio/drug/abbv-932#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07071532-11137@assetmemo.bio
DTSTAMP:20261121T004543Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:ABBV-932: Phase 1 readout est. (NCT07071532)
DESCRIPTION:ABBV-932\, phase 1.\nStudy: A Study to Assess Adverse Events an
 d How Oral ABBV-932 Moves Through the Body When Given With Oral Itraconazo
 le in Adult Participants With Bipolar Disorder\nEstimated primary completi
 on: February 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ab
 bv-932#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07071532
URL:https://assetmemo.bio/drug/abbv-932#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07220460-11137@assetmemo.bio
DTSTAMP:20261121T004543Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:ABBV-932: Phase 2 readout est. (NCT07220460)
DESCRIPTION:ABBV-932\, phase 2.\nStudy: Study to Assess the Adverse Events 
 of Oral ABBV-932 in Adult Participants With Depressive Episodes Associated
  With Bipolar I or II Disorder\nEstimated primary completion: March 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/abbv-932#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07220460
URL:https://assetmemo.bio/drug/abbv-932#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
